I'm LongbridgeAI. Here is the key information I extracted- Key corporate developments involved a 1.5 billion USD financing agreement with Blackstone Life Sciences for GLP-1 clinical trials and adjustments to its product portfolio.…
The Week
Pfizer (PFE) fell 1.7% this week to close at $28.89, while the S&P 500 gained 2.51%, leaving the stock about 4.21 percentage points behind the benchmark. The week was front-loaded: Monday opened at $29.59 and closed at $29.23, with Tuesday and Wednesday edging up to $29.36 and $29.45. Thursday, 12 November, opened at $29.746 but faded to close at $28.83, and Friday, 13 November, slid further to a weekly low of $28.62 before settling at $28.89. Weekly amplitude was 3.89%, with trading volume roughly in line with the 60-day median. The stock sits below its 20-day moving average of $29.793 but above the 60-day average of $28.73.
Key Events
The main thread this week was the obesity (GLP-1) pipeline and portfolio adjustments. On Wednesday, 11 November, Pfizer and Blackstone Life Sciences announced a strategic funding agreement under which Blackstone is backing Pfizer’s obesity programme with a $1.5bn fund in exchange for a slice of future sales. A day earlier, CEO Albert Bourla joined the Jefferies Healthcare Conference, saying Pfizer still believes it can lead the GLP-1 market even though its drug may not arrive until 2028.
Alongside the GLP-1 push came an exit decision: on Friday, 13 November, Pfizer confirmed it will stop selling Premarin, a menopause hormone therapy, in Canada. A separate global development surfaced on Saturday, 14 November, after the trading week had ended, with the news that Pfizer and Innovent’s GLP-1 drugs were added to China’s national insurance for diabetes treatment.
Analyst Ratings
Across 28 institutions covering Pfizer, 8 rate it buy, 1 overweight, 17 hold, 1 underweight and 1 sell. The consensus rating is hold, with a consensus target of $30.22115, about 4.6% above the current price of $28.89. The target range is wide—$37 at the top and $25 at the bottom, a $12 gap—pointing to clear dispersion among analysts. Within the pharmaceutical sector’s 208 covered names, Pfizer ranks third by analyst rating.
The Week Ahead
The coming week is heavy on US macro data. Monday, 16 November, brings the New York Fed manufacturing index, where consensus expects a drop from the prior 25.5 to 18. Tuesday, 17 November, is the busy day, with retail sales, retail sales ex-autos, industrial production and the NAHB housing market index all due. For Pfizer itself, the next major corporate event sits further out: the FY2026 annual results on 2 February 2027, due pre-market, with consensus estimates of $1.5433 EPS and $63.1bn revenue. The GLP-1 funding deal and the Canada product exit may also see follow-up disclosures worth tracking.
In Short
Pfizer underperformed the market this week, but the news flow carried weight: the $1.5bn Blackstone commitment keeps the GLP-1 narrative moving, while the Premarin exit from Canada and the China insurance inclusion for the Innovent GLP-1 drug signal continued repositioning of the portfolio. Analysts remain at ‘hold’, and although the consensus target implies about 4.6% upside, the $12 gap between high and low targets reflects uncertainty about the earnings path. On valuation, the latest P/E sits around 40.8x and P/B around 1.85x—not obviously cheap. The question going forward is whether the GLP-1 collaboration yields clearer clinical progress, and how retail and industrial data shape broader risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
